Literature DB >> 16785317

Metabolism of bergamottin by cytochromes P450 2B6 and 3A5.

Ute M Kent1, Hsia-lien Lin, Kathleen R Noon, Danni L Harris, Paul F Hollenberg.   

Abstract

Cytochromes P450 (P450) 2B6 and 3A5 are inactivated by bergamottin (BG). P450 2B6 metabolized BG primarily to M3 and M4 and one minor metabolite (M1). The metabolites were analyzed, and the data indicated that M1 was bergaptol, M3 was 5'-OH-BG, and M4 was a mixture of 6'- and 7'-OH-BG. Because 6'- and 7'-OH-BG were the primary metabolites, it suggested that P450 2B6 preferentially oxidized the geranyloxy chain of BG. Metabolism of BG by P450 3A5 resulted in three major metabolites: [bergaptol, M3 (5'-OH-BG), and M5 (2'-OH-BG)], and two minor metabolites [M2 (6',7'-dihydroxy-BG) and M4 (6'- and 7'-OH-BG)]. Because bergaptol was the most abundant metabolite formed, it suggested that P450 3A5 metabolized BG mainly by cleaving the geranyl-oxy chain. Molecular modeling studies confirmed that docking of BG in the P450 2B6 active site favors oxidation in the terminal region of the geranyl-oxy chain, whereas positioning the 2'-carbon of BG nearest the heme iron is preferred by P450 3A5. Glutathione (GSH)-BG conjugates were formed by both P450. Each enzyme predominantly formed conjugates with m/z values of 662. Tandem mass spectrometry analysis of the GSH conjugates indicated that the oxidation forming a reactive intermediate occurred on the furan moiety of BG, presumably through the initial formation of an epoxide at the furan double bond. The data indicate that oxidation of the geranyl-oxy chain resulted in the formation of stable metabolites of BG, whereas oxidation of the furan ring produced reactive intermediates that may be responsible for binding to and inactivating P450 2B6 and 3A4.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16785317     DOI: 10.1124/jpet.105.099887

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  7 in total

1.  Identification of the residue in human CYP3A4 that is covalently modified by bergamottin and the reactive intermediate that contributes to the grapefruit juice effect.

Authors:  Hsia-Lien Lin; Cesar Kenaan; Paul F Hollenberg
Journal:  Drug Metab Dispos       Date:  2012-02-16       Impact factor: 3.922

2.  Roles of Residues F206 and V367 in Human CYP2B6: Effects of Mutations on Androgen Hydroxylation, Mechanism-Based Inactivation, and Reversible Inhibition.

Authors:  Hsia-Lien Lin; Haoming Zhang; Cesar Kenaan; Paul F Hollenberg
Journal:  Drug Metab Dispos       Date:  2016-08-18       Impact factor: 3.922

Review 3.  Reactive metabolites in the biotransformation of molecules containing a furan ring.

Authors:  Lisa A Peterson
Journal:  Chem Res Toxicol       Date:  2012-10-24       Impact factor: 3.739

Review 4.  Molecular characterization of CYP2B6 substrates.

Authors:  Sean Ekins; Manisha Iyer; Matthew D Krasowski; Evan D Kharasch
Journal:  Curr Drug Metab       Date:  2008-06       Impact factor: 3.731

5.  Structures of human cytochrome P450 1A1 with bergamottin and erlotinib reveal active-site modifications for binding of diverse ligands.

Authors:  Aaron G Bart; Emily E Scott
Journal:  J Biol Chem       Date:  2018-09-25       Impact factor: 5.157

Review 6.  Phytochemicals That Interfere With Drug Metabolism and Transport, Modifying Plasma Concentration in Humans and Animals.

Authors:  Josefina Gómez-Garduño; Renato León-Rodríguez; Radamés Alemón-Medina; Beatriz E Pérez-Guillé; Rosa E Soriano-Rosales; Ailema González-Ortiz; Juan L Chávez-Pacheco; Edelmira Solorio-López; Paola Fernandez-Pérez; Liliana Rivera-Espinosa
Journal:  Dose Response       Date:  2022-09-21       Impact factor: 2.623

7.  Characterization and Purification of Bergamottin from Citrus grandis (L.) Osbeck cv. Yongjiazaoxiangyou and Its Antiproliferative Activity and Effect on Glucose Consumption in HepG2 cells.

Authors:  Yilong Liu; Chuanhong Ren; Yunlin Cao; Yue Wang; Wenyi Duan; Linfeng Xie; Chongde Sun; Xian Li
Journal:  Molecules       Date:  2017-07-20       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.